PRINCETON, N.J., March 23 /PRNewswire-FirstCall/ -- Cytogen Corporation today announced that data from clinical studies related to the company’s product QUADRAMET(R) (samarium Sm-153 lexidronam injection) will be presented at the American Association for Cancer Research (AACR) annual meeting April 1-5 in Washington, D.C. and the 42nd American Society of Clinical Oncology (ASCO) annual meeting June 2-6 in Atlanta, Georgia. The company also announced that clinical data from a recent study involving its second marketed product, PROSTASCINT(R) (capromab pendetide), will be presented at the American Urological Association (AUA) annual meeting May 20- 25 in Atlanta, Georgia.
“We are especially pleased that interim data will be presented from one of the first combination trials of QUADRAMET with the protease inhibitor bortezomib (Velcade(R), Millennium Pharmaceuticals, Inc.), for the treatment of multiple myeloma, and to provide an update on the emerging role of QUADRAMET with immunotherapy approaches for the treatment of prostate and other cancers,” stated Michael D. Becker, president and chief executive officer of Cytogen. “Throughout 2006, we look forward to the presentation and publication of additional data from more than a dozen ongoing clinical development programs assessing the synergies of QUADRAMET in combination with different chemotherapeutic, biologic, and immunotherapeutic approaches to treat a range of cancers.”
AACR
The following abstracts will be presented at the AACR annual meeting in April and are currently available on the AACR website at http://www.aacr.org, which is not part of this press release:
- “Use of Samarium-153 (QUADRAMET) to modulate phenotype and enhance killing of tumor cells” will be presented on Tuesday, April 4 from 1:00 p.m. to 5:00 p.m. (Abstract # 4398); and - “Targeted internal radiotherapy for osteosarcoma: Isolated limb perfusion using a bone seeking radiopharmaceutical (153Sm-EDTMP)” will be presented on Wednesday, April 5 from 8:00 a.m. to 12:00 p.m. (Abstract # 5194). ASCO
The Scientific Program Committee of ASCO has selected the following abstract for presentation at its 2006 ASCO Annual Meeting in June:
- “Phase I study of bortezomib and 153Sm-lexidronam combination for refractory and relapsed multiple myeloma” will be presented in the Lymphoma and Plasma Cell Disorders General Poster Session. AUA
The following abstract will be presented at the AUA annual meeting in May and is currently available on the AUA website at http://www.auanet.org, which is not part of this press release:
- “SPECT/CT Capromab Pendetide Independently Predicts bDFS in Long Term Outcome Study” will be presented on Wednesday, May 24 from 1:00 p.m. to 3:00 p.m. during a Podium Session on Prostate Cancer: Staging (II) (Abstract # 1649). NOTE:
QUADRAMET is indicated for the relief of pain in patients with confirmed osteoblastic metastatic bone lesions that enhance on radionuclide bone scan. This press release describes clinical applications that differ from that reported in the QUADRAMET package insert.
PROSTASCINT is indicated as a diagnostic imaging agent in newly diagnosed patients with biopsy-proven prostate cancer, thought to be clinically localized after standard diagnostic evaluation and who are thought to be at high risk for pelvic lymph node metastases. PROSTASCINT is also indicated as a diagnostic imaging agent in post-prostatectomy patients with a rising PSA and a negative or equivocal standard metastatic evaluation in whom there is a high clinical suspicion of occult metastatic disease. This press release describes clinical applications and imaging performance that differs from that reported in the PROSTASCINT package insert.
A copy of the full prescribing information for QUADRAMET and PROSTASCINT, including warnings, precautions, adverse events and other safety information, may be obtained in the U.S. from Cytogen Corporation by calling toll-free 800-833-3533 or by visiting the web site at http://www.cytogen.com, which is not part of this press release.
ABOUT CYTOGEN CORPORATION
Founded in 1980, Cytogen Corporation of Princeton, NJ is a biopharmaceutical company dedicated to improving the lives of patients with cancer by acquiring, developing and commercializing innovative molecules targeting the sites and stages of cancer progression. Cytogen’s marketed products include QUADRAMET(R) (samarium Sm-153 lexidronam injection) and PROSTASCINT(R) (capromab pendetide) kit for the preparation of Indium In-111 capromab pendetide in the United States. Cytogen also has exclusive United States marketing rights to COMBIDEX(R) (ferumoxtran-10) for all applications, and the exclusive right to market and sell ferumoxytol (previously Code 7228) for oncology applications in the United States. Cytogen’s development pipeline consists of therapeutics targeting prostate-specific membrane antigen (PSMA), a protein highly expressed on the surface of prostate cancer cells and the neovasculature of solid tumors. Full prescribing information for the Company’s products is available at http://www.cytogen.com or by calling 800-833-3533. For more information, please visit the Company’s website at http://www.cytogen.com, which is not part of this press release.
This press release contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and investors are cautioned not to put any undue reliance on any forward-looking statement. There are a number of important factors that could cause Cytogen’s results to differ materially from those indicated by such forward-looking statements. In particular, Cytogen’s business is subject to a number of significant risks, which include, but are not limited to: the risk of obtaining additional capital; the risk of obtaining the necessary regulatory approvals; the risk of whether products result from development activities; the risk of shifts in the regulatory environment affecting sales of Cytogen’s products such as third-party payor reimbursement issues; the risk associated with Cytogen’s dependence on its partners for development of certain projects, as well as other factors expressed from time to time in Cytogen’s periodic filings with the Securities and Exchange Commission (the “SEC”). As a result, this press release should be read in conjunction with Cytogen’s periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Cytogen undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Cytogen Corporation
CONTACT: Jonathan Fassberg of The Trout Group, +1-212-477-9007 x16, forCytogen Corporation
Web site: http://www.cytogen.com//
